Welcome to our dedicated page for SERA PROGNOSTICS SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
SERA PROGNOSTICS, INC. General Counsel Benjamin Jackson reported a small mandated share sale related to equity compensation. On March 11, 2026, he sold 1,027 shares of Class A common stock in a block trade at a weighted average price of $2.04 per share.
According to the disclosure, the sale was executed solely to cover tax withholding obligations triggered by the vesting of restricted stock units under a required “sell to cover” arrangement, meaning it was not a discretionary trade. After this transaction, Jackson directly holds 114,720 shares of Sera Prognostics common stock.
SERA PROGNOSTICS, INC. Chief Information Officer Robert Gardner reported an open-market sale of 716 shares of Class A common stock at a weighted average price of $2.04 per share. This reduced his direct holdings to 76,712 shares.
According to the footnotes, the sale was mandated to cover tax withholding obligations tied to vesting restricted stock units under a required “sell to cover” arrangement, and is described as a non-discretionary transaction rather than an elective share sale. The shares were sold as part of a block trade at prices ranging from $1.90 to $2.30 per share.
Sera Prognostics Chief Scientific Officer John J. Boniface reported an open-market sale of 1,517 shares of Class A common stock at a weighted average price of $2.04 per share. The sale was used to cover tax withholding obligations related to vesting restricted stock units and was mandated by the company’s sell-to-cover policy, not a discretionary trade. After the transaction, he directly holds 145,842 shares. The shares were sold in a block trade at prices ranging from $1.90 to $2.30 per share.
Sera Prognostics Chief Financial Officer Austin Aerts reported mandatory share sales tied to tax withholding on vested RSUs. On March 10 and March 11, he sold a total of 7,088 shares of Class A common stock in open-market block trades to cover tax obligations.
The sales occurred at weighted average prices of $1.90 and $2.04 per share, within disclosed ranges from $1.77 to $2.36. After these transactions, Aerts directly held 264,452 shares of Sera Prognostics common stock. The filing states these were not discretionary trades.
Insider filed a Form 144 to sell Class A Common shares. The form lists a proposed sale of 2,973 shares to be effected through Morgan Stanley Smith Barney LLC on 03/11/2026. The filing also records prior dispositions of 4,155 shares on 12/10/2025 and 22,639 shares on 03/10/2026.
SERA filed a Form 144 reporting a proposed sale of Class A Common stock tied to restricted stock unit vesting with an effective date of 03/11/2026. The filing lists recent dispositions by Paul Kearney on 12/10/2025 and 03/09/2026.
SERA reported insider sale activity via a Form 144 notice. The filing lists sales by Benjamin Jackson of 892 shares on 12/10/2025 and 3,119 shares on 03/09/2026. The filing also lists 1,027 Class A shares tied to restricted stock unit vesting with a 03/11/2026 vesting date.
Robert Harrison reports proposed resale of 716 shares of Class A Common associated with Restricted Stock Unit vesting on 03/11/2026.
The filing also lists completed open‑market sales by Robert Harrison: 616 shares on 12/10/2025, 2,000 shares on 12/30/2025, 2,000 shares on 01/27/2026, 2,000 shares on 02/24/2026, and 3,360 shares on 03/09/2026.
SERA submitted a Form 144 notice to sell Class A Common shares tied to Restricted Stock Unit vesting. The filing lists Class A Common securities with a proposed sale date of 03/11/2026 and shows an entry of 1,517 and another figure 3,097 adjacent to the security line. The filing also reports securities sold during the past three months by John J. Boniface: 1,332 shares on 12/10/2025 and 3,038 shares on 03/09/2026.
SERA filed a Form 144 disclosing intended sales of Class A Common stock tied to recent RSU vesting and open-market dispositions. The filing lists a Restricted Stock Unit vesting of 6,069 Class A shares on 03/10/2026 and shows sales by Austin Aerts of 873 shares on 12/10/2025, 674 shares on 03/09/2026, and 6,069 shares on 03/10/2026. The cover lists 38,594,793 shares with a date of 03/11/2026 and trading venue NASDAQ (contextual baseline).